Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilbert Koch

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Klinische Padiatrie|June 8, 2021
Nadia S Eugster, Florence Corminboeuf, Gilbert Koch, et al.
Pediatric Research|April 1, 2019
Enhanced early prediction of clinically relevant neonatal hyperbilirubinemia with machine learningImant Daunhawer, Severin Kasser, Gilbert Koch, et al.
Journal of Clinical Pharmacology|May 23, 2025
Influence of Disease Type and Activity on Adalimumab Exposure in Children with Inflammatory Rheumatic DiseasesKlervi Golhen, Tatjana Welzel, Andrew Atkinson, et al.
Journal of Pharmaceutical Sciences|March 18, 2024
Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part I: Effects on Signal Transduction Pathways Related to Tumor GrowthXin Miao, Shichen Shen, Gilbert Koch, et al.
The Journal of Clinical Endocrinology and Metabolism|December 22, 2017
Release and Decay Kinetics of Copeptin vs AVP in Response to Osmotic Alterations in Healthy VolunteersWiebke K Fenske, Ingeborg Schnyder, Gilbert Koch, et al.
Journal of Pharmaceutical Sciences|November 2, 2023
Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part II: Cell Cycle, DNA Damage Response, and Apoptosis PathwaysXin Miao, Gilbert Koch, Shichen Shen, et al.
Pediatric Rheumatology Online Journal|January 22, 2026
Evaluation of adalimumab tapering regimens in children and adolescents with juvenile idiopathic arthritis in remission: a simulation studyDominic S Bräm, Verena Gotta, Gilbert Koch, et al.
Clinical Pharmacokinetics|August 5, 2021
Infliximab Treatment Does Not Lead to Full TNF-α Inhibition: A Target-Mediated Drug Disposition ModelDavid Ternant, Marc Pfister, Olivier Le Tilly, et al.
Frontiers in Medicine|May 19, 2023
Clinically practical pharmacometrics computer model to evaluate and personalize pharmacotherapy in pediatric rare diseases: application to Graves' diseaseBritta Steffens, Gilbert Koch, Pascal Gächter, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 12, 2021
Modeling of levothyroxine in newborns and infants with congenital hypothyroidism: challenges and opportunities of a rare disease multi-center studyGilbert Koch, Britta Steffens, Stephanie Leroux, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Klinische Padiatrie|June 8, 2021
Nadia S Eugster, Florence Corminboeuf, Gilbert Koch, et al.
Pediatric Research|April 1, 2019
Enhanced early prediction of clinically relevant neonatal hyperbilirubinemia with machine learningImant Daunhawer, Severin Kasser, Gilbert Koch, et al.
Journal of Clinical Pharmacology|May 23, 2025
Influence of Disease Type and Activity on Adalimumab Exposure in Children with Inflammatory Rheumatic DiseasesKlervi Golhen, Tatjana Welzel, Andrew Atkinson, et al.
Journal of Pharmaceutical Sciences|March 18, 2024
Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part I: Effects on Signal Transduction Pathways Related to Tumor GrowthXin Miao, Shichen Shen, Gilbert Koch, et al.
The Journal of Clinical Endocrinology and Metabolism|December 22, 2017
Release and Decay Kinetics of Copeptin vs AVP in Response to Osmotic Alterations in Healthy VolunteersWiebke K Fenske, Ingeborg Schnyder, Gilbert Koch, et al.
Journal of Pharmaceutical Sciences|November 2, 2023
Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part II: Cell Cycle, DNA Damage Response, and Apoptosis PathwaysXin Miao, Gilbert Koch, Shichen Shen, et al.
Pediatric Rheumatology Online Journal|January 22, 2026
Evaluation of adalimumab tapering regimens in children and adolescents with juvenile idiopathic arthritis in remission: a simulation studyDominic S Bräm, Verena Gotta, Gilbert Koch, et al.
Clinical Pharmacokinetics|August 5, 2021
Infliximab Treatment Does Not Lead to Full TNF-α Inhibition: A Target-Mediated Drug Disposition ModelDavid Ternant, Marc Pfister, Olivier Le Tilly, et al.
Frontiers in Medicine|May 19, 2023
Clinically practical pharmacometrics computer model to evaluate and personalize pharmacotherapy in pediatric rare diseases: application to Graves' diseaseBritta Steffens, Gilbert Koch, Pascal Gächter, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 12, 2021
Modeling of levothyroxine in newborns and infants with congenital hypothyroidism: challenges and opportunities of a rare disease multi-center studyGilbert Koch, Britta Steffens, Stephanie Leroux, et al.
Pageof 6